New MRI Biomarkers in Head and Neck Cancers

This study is looking at new ways to use Magnetic Resonance Imaging (MRI) to get more information about head and neck cancers and thyroid cancers. MRI uses magnetic fields and radio waves to create detailed pictures of your body. This study will use special MRI techniques, including diffusion MRI, to see if they can help doctors understand how tumors respond to treatment. You would have MRI scans before treatment, and some patients receiving radiation therapy would have weekly scans during treatment. All participants would also have scans a few months after treatment finishes. The study aims to see if these new MRI methods can identify early signs of how well treatment is working.

Study design: This is an observational study, meaning participants will be monitored without receiving an experimental treatment. It plans to enroll 200 participants.
What's involved: You would have MRI scans before treatment, and some patients would have weekly scans during radiation therapy. All participants would also have scans two and four months after treatment completion.
Compensation: Not stated in the trial record.
Follow-up: The study will measure treatment response and look for biomarkers for one year after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

New MRI Biomarkers in Head and Neck Cancers

Recruiting

Not specifiedAges 18+Observational

Memorial Sloan Kettering Cancer Center

~200 participants

Updated 2026-04-14 on ClinicalTrials.gov

What's tested:MRI examinations

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

For group 1: number of patients that have biomarkers that maybe early response to therapy indicators

Measured over 1 year

+1 more outcome measured

Conditions

Head and Neck Cancer

Thyroid Cancer

Where it's being run

1 sites across 1 states

New York1

Study leadership

Amita Dave, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Amita Dave, PhD

[email protected]

212-639-3184

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age ≥ 18 years

Group 1 patients: Presence of a suspicious metastatic lesion or suspicious for recurrent disease in the head and neck region.

Group 2 patients:

Biopsy proven recurrent or metastatic or definitive head and neck cancer or (differentiated and undifferentiated) thyroid cancers in the head and neck region only.

Patients planning to undergo reatment at MSK

Exclusion

Patient would require anesthesia for the study

Patients who are claustrophobic

Patients selecting treatment outside of MSK

Known reaction to Gd based contrast agent

Patients who have presence of a known contradiction to MRI

Pacemaker

Aneurysm clips

Patients with implants that are contradicted for MR imaging will be excluded

Pregnant

Age and mental status wherein he /she is unable to cooperate for MRI study

What this trial measures

For group 1: number of patients that have biomarkers that maybe early response to therapy indicators1 year
The study is designed to determine if the MRI will provide quantitative imaging biomarkers to predict or assess early treatment response in R/M head and neck cancers. The MR data will be compared with clinical follow-up data. Additional sequence parameters.
For group 2: number of patients response to treatment1 year
will be assessed using ROC curves with RECIST with the RECIST version 1.1 response as the gold standard and change in DW-MRI and image feature metrics as predictors.

Trialytics